Fig. 5.

A decatenation G₂ checkpoint gene expression signature correlates with clinical outcomes of breast cancer patients. a gene expression signature that positively correlated with decatenation G₂ checkpoint function in the breast cancer cell line panel was identified and its relationship with clinical outcomes in the METABRIC study was assessed using a Cox proportional hazards model. A high expression of the decatenation G₂ checkpoint signature was associated with better overall survival (OS) in all breast tumors (log rank p = 0.0176). b For the LumA subtype of breast tumors, high expression of the decatenation G₂ checkpoint was associated with better OS outcomes (Log Rank p = 0.01741). c Median decatenation G₂ checkpoint signature varies with intrinsic molecular subtype; LumA and LumB breast tumors exhibited the lowest median expression of the decatenation G₂ checkpoint signature. HR: hazard ratio, OS: overall survival, CI: confidence intervals